If you have been reading about Reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-28. Numbers and descriptions here follow the published literature rather than marketing material.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
=== Response to injury === Myomesin has also been shown to play a role in injury response and expression. It was previously thought that myosin chaperones were the first alert of sarcomere damage, but recent studies show a flux of expression the gene myomesin1a much earlier than that of the myosin, suggesting that there is a myomesin-dependent injury response pathway in striated muscles. Additionally, it is thought that this gene could be used as an enhanced biomarker for sarcomere damage compared to the current biomarker, muscle creatine kinase (CKM). When tested in vivo in zebrafish, myom1a expression was displayed much earlier than creatine kinase, indicating that the latter is less specific to muscle diseases. This supports the use of myomesin assays for detection of muscular pathologies earlier than the current practices.
The treatment of choice for this condition is the surgical application of epidural blood patches, which has a higher success rate than conservative treatments of bed rest and hydration. Through the injection of a person's own blood into the area of the hole in the dura, an epidural blood patch uses blood's clotting factors to clot the sites of holes. The volume of autologous blood and number of patch attempts for patients is highly variable. One-quarter to one-third of those with a sCSFL patients do not have relief of symptoms from epidural blood patching. Finding the location of a cerebrospinal fluid leak is not required prior to using an epidural blood patch as initial lumbar epidural blood patches often provide relief of symptoms and resolve the leak without further intervention.
Tramadol, sold under the brand name Tramal among others, is an opioid pain medication and a serotonin–norepinephrine reuptake inhibitor (SNRI) used to treat moderate to severe pain. When taken by mouth in an immediate-release formulation, the onset of pain relief usually begins within an hour. It is also available by injection. It is available in combination with paracetamol (acetaminophen). As is typical of opioids, common side effects include constipation, itchiness, and nausea. Serious side effects may include hallucinations, seizures, increased risk of serotonin syndrome, decreased alertness, and drug addiction. A change in dosage may be recommended in those with kidney or liver problems. It is not recommended in those who are at risk of suicide or in those who are pregnant. While not recommended in women who are breastfeeding, those who take a single dose should not generally have to stop breastfeeding. Tramadol is converted in the liver to O-desmethyltramadol (desmetramadol), an opioid with a stronger affinity for the μ-opioid receptor. Tramadol was patented in 1972 and launched under the brand name Tramal in 1977 by the West German pharmaceutical company Grünenthal GmbH. In the mid-1990s, it was approved in the United Kingdom and the United States. It is available as a generic medication and marketed under many brand names worldwide. In 2023, it was the 36th most commonly prescribed medication in the United States, with more than 16 million prescriptions.
Sources: en.wikipedia.org
=== Pharmacokinetics === Absorption: Flupentixol: Readily absorbed in the GI tract. Distribution: Flupentixol: >95% bound to plasma proteins; widely distributed in the body and crosses the blood brain barrier. Metabolism: Flupentixol: Extensively hepatic metabolism. Excretion: Flupentixol: Excreted in urine and faeces in the form of many metabolites.
=== July === 1 July – Dennis Lattimer, muralist (born 1946). 2 July – Des Gorman, diving and hyperbaric medicine specialist (University of Auckland) and health bureaucrat (born 1953). 3 July Terry Brown, brothel owner (born 1956/1957). (death announced on this date) Hilary Stace, disability and autism advocate, eugenics researcher (born 1954) 5 July – Tim Bray, actor, comedian, and children's theatre founder (born 1964). 6 July – Kay Bradford, child and adolescent psychiatrist (born 1930). 9 July – Bruce Harris, legal academic (University of Otago, University of Auckland). 11 July Bert Brownlie, economist (University of Auckland, University of Canterbury) and university administrator, University of Canterbury vice-chancellor (1977–1998) (born 1932). Alex McNabb, mathematician (DSIR), Fellow of the Royal Society of New Zealand (since 1985) (born 1930). 12 July – Heather Roe, field hockey player (national team) (born 1939). 15 July – Neill Price, firefighter, local politician and community leader, Waimakariri District Councillor (1989–1998) (born 1936). 16 July Chris Faiumu, musician (Fat Freddy's Drop) and reggae-dub producer. Bruce McTavish, boxing referee (born 1940). Andrew Oliver, oldest person known to have survived with Fryns–Aftimos syndrome (born c. 1984). 17 July Barrie Downey, business executive (Fletcher Challenge) (born 1930). Don McIntosh, rugby union player (Wellington, national team) (born 1931). Greer Twiss, sculptor (Karangahape Rocks) and educator (University of Auckland), Arts Foundation of New Zealand Icon (since 2011) (born 1937).
=== Anion exchange === Anion exchange sorbents are derivatized with positively charged functional groups that interact and retain negatively charged anions, such as acids. Strong anion exchange sorbents contain quaternary ammonium groups that have a permanent positive charge in aqueous solutions, and weak anion exchange sorbents use amine groups which are charged when the pH is below about 9. Strong anion exchange sorbents are useful because any strongly acidic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong acid a weak anion exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes the charge of either the analyte, the stationary phase, or both. Once the charge is neutralized, the electrostatic interaction between the analyte and the stationary phase no longer exists and the analyte will elute from the cartridge.
In 1946, the Atomic Bomb Casualty Commission (ABCC) was established by the National Research Council of the National Academy of Sciences by order of U.S. President Harry S. Truman to study the long-term effects of radiation on survivors of the atomic bombings. In 1975, the ABCC was replaced by the Radiation Effects Research Foundation (RERF). Organizations such as the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), founded in 1955, and the National Academy of Sciences - Advisory Committee on the Biological Effects of Ionizing Radiation (BEIR Committee), founded in 1972, analyze the effects of radiation exposure on humans on the basis of atomic bomb victims who have been examined and, in some cases, medically monitored for decades. They determine the course of the mortality rate as a function of the age of the radiation victims in comparison with the spontaneous rate, and also the dose-dependency of the number of additional deaths. To date, 26 UNSCEAR reports have been published and are available online, most recently in 2017 on the effects of the Fukushima nuclear accident. By 1949, Americans felt increasingly threatened by the possibility of nuclear war with the Soviet Union and sought ways to survive a nuclear attack. The U.S. Federal Civil Defense Administration (USFCDA) was created by the government to educate the public on how to prepare for such an attack. In 1951, with the help of this agency, a children's educational film was produced in the U.S.
Sources: en.wikipedia.org
=== Pain === KOR agonists have been clinically employed as analgesics, with examples including butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, and eptazocine. Unlike MOR agonists, KOR agonists do not cause respiratory depression and have lower abuse potential, but centrally-mediated side effects such as dysphoria, hallucinations, and dissociation have limited their clinical utility. Nalorphine and nalmefene are dual MOR antagonists and KOR agonists used clinically as antidotes for opioid overdose, but the specific role of KOR activation to their efficacy remains uncertain as KOR agonists do not reverse respiratory depression induced by MOR activation and thus cannot serve as standalone antidotes for this purpose. Peripherally selective KOR agonists display analgesic efficacy mediated through anti-inflammatory effects on immune cells and nociceptors. CR665 and difelikefalin (CR845, FE-202845) have been investigated clinically; marking the first peripherally-restricted KOR agonist to reach regulatory approval, though none have yet been approved specifically for pain indication. Recent evidence supports the therapeutic potential of mixed KOR/MOR agonists and KOR-biased ligands as adjuncts to conventional analgesics in inflammatory and cancer pain, with particular promise for chronic neuropathic pain syndromes.
== Mechanism of action == Tigecycline is a broad-spectrum antibiotic that acts as a protein synthesis inhibitor. It exhibits bacteriostatic activity by binding to the 30S ribosomal subunit of bacteria and thereby blocking the interaction of aminoacyl-tRNA with the A site of the ribosome. In addition, tigecycline has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila. Studies have shown that tigecycline binds to the 70S ribosome with 5 fold and >100 fold greater affinity than minocycline and tetracycline, respectively . As previously mentioned, tigecycline still binds to the A site of the 30S ribosomal subunit, however the binding of the novel antibiotic involves substantial interactions with residues of helix H34 of that same subunit. These interactions are not observed in the binding of tetracycline. The findings indicate that tigecycline likely has a unique mechanism of action that prevents inhibition from ribosomal protection. It is a third-generation tetracycline derivative within a class called glycylcyclines which carry a N,N-dimethyglycylamido (DMG) moiety attached to the 9-position of tetracycline ring D. With structural modifications as a 9-DMG derivative of minocycline, tigecycline has been found to improve minimal inhibitory concentrations against Gram-negative and Gram-positive organisms, when compared to tetracyclines.
=== Second year === Reportedly, from about three dozen officers on a promotion list, most of them white men, Hegseth blocked the promotion of two women and two Black officers. According to The New York Times, "It is exceedingly rare that a one-star list draws such intense scrutiny from a defense secretary." In early 2026, reports emerged of the dismissal or retirement of several senior military commanders amid rising military tensions between the United States and Iran and broader instability in the Middle East. These developments were described as part of a broader shift in Pentagon leadership, with multiple senior officers reportedly stepping down or being removed from their positions. Media outlets reported concerns regarding internal disagreements within the defense establishment and the potential impact on the stability and operational readiness of the military command structure. Some reactions criticized the rationale for the reductions, with concerns that the large-scale removal of senior officers without clear justification could affect military readiness. In April 2026, Hegseth repealed the requirement for basic military trainees to receive the influenza vaccine. The requirement was restored in July 2026 after an outbreak at Joint Base San Antonio hospitalized four and killed one trainee. In July 2026, Hegseth announced that the military would begin testing service members' testosterone levels and providing hormone therapy. The policy was rescinded in September 2026.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.